Category: Press

For Immediate Release – ASCO 2022 Abstract #9004 Contact: Frank DeSanto, Communications Manager, SWOG Cancer Research Network, fdesanto@swog.org, 210.718.2941 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.org, 202.944.6708 Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had…

For Immediate Release Contact: Wendy Lawton, Communications Manager, SWOG Cancer Research Network, lawtonw@ohsu.edu, 503-348-8675 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.og  202.944.6708 Lung-MAP Translational Discoveries Shared at 2020 World Conference on Lung Cancer WASHINGTON, DC – Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine…

A majority of cancer patients don’t understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP). In a September 9 presentation at the World Conference on Lung Cancer in Barcelona, Lung-MAP investigator Joshua A. Roth, PhD,…

For Immediate Release Jan. 29, 2019 Please Contact: Ryan Hohman, Vice President – Public Affairs, Friends of Cancer Research rhohman@focr.org; 202-944-6708 Wendy Lawton, Communications Manager, SWOG lawtonw@ohsu.edu; 503.348.8675 Lung-MAP Precision Medicine Trial Expands To Include More Patients Washington, DC – The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the…

For Immediate Release Feb. 29, 2016 Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org Wendy Lawton, Communications and Public Relations Manager, SWOG: 503.348.8675 –lawtonw@ohsu.edu Lung-MAP Precision Medicine Trial Makes Exciting Changes, With New Science and Treatment Options for Patients Lung-MAP, the most collaborative and comprehensive lung cancer clinical…

For Immediate Release Media Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Statement from Lung-MAP Clinical Trial Leadership Regarding FDA Approval of Nivolumab On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced…

For Immediate Release Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Innovative Lung-MAP Lung Cancer Trial Open and Enrolling Patients at over 400 Sites in 39 States Trial will Close One of Five Trial…

The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Foundation Medicine and Friends of Cancer Research, and in partnership with many advocacy organizations, today launched the “Don’t Guess. Test.” campaign to expand awareness and educate patients about precision medicine and the importance of comprehensive genomic testing in lung cancer. Through extensive grassroots and…

For Immediate Release Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Lung-MAP Collaborative Clinical Trial Rapidly Expanding Across the Country Groundbreaking study in squamous cell lung cancer opens at more than a hundred and…